{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:39:40Z","timestamp":1777934380904,"version":"3.51.4"},"reference-count":7,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Granulocyte\u2013colony stimulating factor (G-CSF) has been approved for use for mobilization of hematopoietic progenitor cells from the marrow into the blood for peripheral blood stem cell collection. Commonly reported side effects of G-CSF include deep throbbing bone pain, severe myalgia and leucocytosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We describe a case of severe hypersensitivity anaphylactoid reaction after filgrastim administration in a healthy stem cell donor. This haploidentical donor was a 38-year old man with sickle cell trait, donating stem cells for his son, a case of sickle cell disease. On administration of G-CSF (10\u2009\u00b5g\/kg) he developed features of anaphylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>He was given supportive care with oxygen, IV fluid bolus, anti histaminics and steroids. The donor had complete recovery and underwent successful bone marrow harvest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There have been various reports of hypersensitivity anaphylactoid reactions in patients undergoing chemotherapy but those associated with the first dose of G-CSF in healthy stem cell donors have rarely been reported.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155219856419","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T13:01:45Z","timestamp":1560603705000},"page":"2056-2058","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Severe hypersensitivity allergic reaction to filgrastim in a healthy stem cell donor"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3511-0977","authenticated-orcid":false,"given":"Divya","family":"Doval","sequence":"first","affiliation":[{"name":"Department of Hemato-oncology and BMT, BLK Superspeciality Hospital, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharma","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Department of Hemato-oncology and BMT, BLK Superspeciality Hospital, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev K","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Hemato-oncology and BMT, BLK Superspeciality Hospital, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipin","family":"Khandelwal","sequence":"additional","affiliation":[{"name":"Department of Hemato-oncology and BMT, BLK Superspeciality Hospital, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"key":"bibr1-1078155219856419","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00384.x"},{"key":"bibr2-1078155219856419","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.812"},{"key":"bibr3-1078155219856419","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.438"},{"key":"bibr4-1078155219856419","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00423-8"},{"key":"bibr5-1078155219856419","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108223250817"},{"key":"bibr6-1078155219856419","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90963-X"},{"key":"bibr7-1078155219856419","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219856419","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219856419","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219856419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:21:17Z","timestamp":1777688477000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219856419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":7,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1177\/1078155219856419"],"URL":"https:\/\/doi.org\/10.1177\/1078155219856419","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]}}}